Enemy -- so, if the effda doesn't allow an intravenous/4 dose protocol and says only 2 like CD12, I sure hope the company just goes ahead anyway and does an intravenous/4 dose trial. What regulatory role would/does the Brazil FDA equivalent play in the trial protocol?